Zi-Guo Yang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Zi-Guo Yang has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
Feng Wang
Department of General Surgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China
1 shared publication- Lehao Ren
Department of Critical Care Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
1 shared publication Pi-Lin Wang
Department of General Surgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China
1 shared publication- Shuye Lin
Department of Gastroenterology, Beijing Chest Hospital, Beijing Tuberculosis and Thoracic Tumor Research Institute, Capital Medical University, Beijing, China
1 shared publication - Wen-Yan Wang
Department of General Surgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China
1 shared publication
Latest Publications
- 2 February 2024
- Published by Springer Nature in Current Medical Science
- Vol. 44 (1) , 156-167
Ki-67 Change in Anthracyline-containing Neoadjuvant Chemotherapy Response in Breast Cancer
Objective Anthracycline-containing regimens are irreplaceable in neoadjuvant chemotherapy (NAC) for breast cancer (BC) at present. However, 30% of early breast cancer (EBC) patients are resistant to anthracycline-containing chemotherapy, leading to poor prognosis and higher mortality. Ki-67 is associated with the prognosis and response to therapy, and it changes after NAC. Methods A total of 105 BC patients who received anthracycline-containing NAC were enrolled. Then, the optimal model of Ki-67 was selected, and its predictive efficacy was analyzed. Immunohistochemistry (IHC) was used to determine the estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER-2) status and Ki-67 level. Fluorescent in situ hybridization (FISH) was used to verify the HER-2 when the IHC score was 2+. Results The post-NAC Ki67 level after treatment with anthracycline drugs was lower than pre-NAC Ki-67 (19.6%±23.3% vs. 45.6%±23.1%, Pvs. 0.0%, P=0.068), and a higher overall response rate (ORR) (73.6% vs. 27.8%, PP=0.002] and ORR (OR=10.001, 95% CI: 3.044–32.858; PP=0.002) and ORR (OR=5.419, 95% CI=1.842–15.943; P=0.002). Conclusions The present study results suggest that ΔKi67 and ΔKi67% are candidate predictors for anthracycline-containing NAC response, and that they may provide various information for further systematic therapy after surgery in clinical practice.
- 2 February 2024
- Published by Springer Nature in Current Medical Science
- Vol. 44 (1) , 156-167
Ki-67 Change in Anthracyline-containing Neoadjuvant Chemotherapy Response in Breast Cancer
Objective Anthracycline-containing regimens are irreplaceable in neoadjuvant chemotherapy (NAC) for breast cancer (BC) at present. However, 30% of early breast cancer (EBC) patients are resistant to anthracycline-containing chemotherapy, leading to poor prognosis and higher mortality. Ki-67 is associated with the prognosis and response to therapy, and it changes after NAC. Methods A total of 105 BC patients who received anthracycline-containing NAC were enrolled. Then, the optimal model of Ki-67 was selected, and its predictive efficacy was analyzed. Immunohistochemistry (IHC) was used to determine the estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER-2) status and Ki-67 level. Fluorescent in situ hybridization (FISH) was used to verify the HER-2 when the IHC score was 2+. Results The post-NAC Ki67 level after treatment with anthracycline drugs was lower than pre-NAC Ki-67 (19.6%±23.3% vs. 45.6%±23.1%, Pvs. 0.0%, P=0.068), and a higher overall response rate (ORR) (73.6% vs. 27.8%, PP=0.002] and ORR (OR=10.001, 95% CI: 3.044–32.858; PP=0.002) and ORR (OR=5.419, 95% CI=1.842–15.943; P=0.002). Conclusions The present study results suggest that ΔKi67 and ΔKi67% are candidate predictors for anthracycline-containing NAC response, and that they may provide various information for further systematic therapy after surgery in clinical practice.